Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.
Awards and honors continue for the PRCA/PRSSA at UAB chapter, where students put their classroom learning into real-world practice, preparing them for careers and vaulting them into the professional world. Students in UA.
UAB Barefield Entrepreneurship Program Hosts National Small Business and Entrepreneurship Conference birminghamtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from birminghamtimes.com Daily Mail and Mail on Sunday newspapers.
3D in vitro human atherosclerosis model for high-throughput drug screening sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.
3D in vitro human atherosclerosis model for high-throughput drug screening medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.